ReviewHeart failure reviews2021
Heart failure and COVID-19.
Review in Heart failure reviews, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 123 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
123 citing papers in PubMed, 4 syntheses or guidelines pooled it, 269 citations in OpenAlex.
- Risk of incident heart failure after COVID-19 recovery: a systematic review and meta-analysis.Heart failure reviews · 2023Pooled it
- COVID-19-associated Brugada pattern electrocardiogram: Systematic review of case reports.Annals of noninvasive electrocardiology : the official journal of the International Society for Holter and Noninvasive Electrocardiology, Inc · 2023Pooled it
- Comorbidities and complications of COVID-19 associated with disease severity, progression, and mortality in China with centralized isolation and hospitalization: A systematic review and meta-analysis.Frontiers in public health · 2022Pooled it
- Pooled it
- Review
- Penalized likelihood optimization for adaptive neighborhood clustering in time-to-event data with group-level heterogeneity.Biostatistics (Oxford, England) · 2026Article
- Self-care and fatigue in individuals hospitalized with decompensated heart failure during the covid-19 pandemic: a cross-sectional study.Revista latino-americana de enfermagem · 2026Observational
- Article
- Deep learning model for diagnosing lupus erythematosus in cardiac patients using ECG and audio spectrograms.Scientific reports · 2025Article
- Incidence of Recurrent Adverse Cardiovascular Events Among Patients With Acute Myocardial Infarction During the First Wave of the COVID-19 Pandemic in Bangladesh: A Prospective Observational Study.Health science reports · 2025Article
- LDA-SCGB: inferring lncRNA-disease associations based on condensed gradient boosting.BMC bioinformatics · 2025Article
- How do Japanese Patients with Chronic Heart Failure View Their Disease, Self-care, and Support?Advances in therapy · 2025Article
- COVID-19 and Myocarditis: Trends, Clinical Characteristics, and Future Directions.Journal of clinical medicine · 2025Review
- Multimodality Imaging Leading the Way to a Prompt Diagnosis and Management of Transthyretin Amyloidosis.Journal of clinical medicine · 2025Article
- Sex and age differences in atypical chief complaints for acute decompensated heart failure in the emergency department.Clinical and experimental emergency medicine · 2025Article
- Article
- COVID-19: A Disease Driven by Protease/Antiprotease Imbalance? A Specific Review Five Years into the Pandemic.Infection and drug resistance · 2025Review
- COVID-19 worsens quality of life in elderly heart failure patients: a clinical study.American journal of translational research · 2025Article
- Syndrome of inappropriate antidiuresis/hyponatremia in COVID-19.Pituitary · 2024Review
- The Impact of Vaccinations Against Respiratory Infections on the Prognosis in Heart Failure Patients.Vaccines · 2024Review
63 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Heart failure is a common disease state that can be encountered at different stages in the course of a COVID-19 patient presentation. New or existing heart failure in the setting of COVID-19 can present a set of unique challenges that can complicate presentation, management, and prognosis. A careful understanding of the hemodynamic and diagnostic implications is essential for appropriate triage and management of these patients. Abnormal cardiac biomarkers are common in COVID-19 and can stem from a variety of mechanisms that involve the viral entry itself through the ACE2 receptors, direct cardiac injury, increased thrombotic activity, stress cardiomyopathy, and among others. The cytokine storm observed in this pandemic can be a culprit in many of the observed mechanisms and presentations. A correct understanding of the two-way interaction between heart failure medications and the infection as well as the proposed COVID-19 medications and heart failure can result in optimal management. Guideline-directed medical therapy for heart failure should not be interrupted for theoretical concerns but rather based on tolerance and clinical presentation. Initiating specific cardiac or heart failure medications to prevent the infection or mitigate the disease is also not an evidence-based practice at this time. Heart failure patients on advanced therapies including those with heart transplantation will particularly benefit from involving the advanced heart failure team members in the overall management if they contract the virus.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.